Strains that harbor such ␤-lactamases are increasing in prevalence worldwide, are among the most important and frequently isolated nosocomial pathogens, and are often additionally resistant to many classes of antibiotics, such as the fluoroquinolones (4). It is known, mainly in Pseudomonas aeruginosa but also in Enterobacteriaceae, that the overexpression of some efflux pumps that confer resistance to fluoroquinolones, often associated with other mechanisms, such as mutations in genes encoding DNA gyrase and topoisomerase IV or acquisition of some plasmid-mediated quinolone-resistance genes, may increase the MIC of ␤-lactam antibiotics, such as ceftazidime (5). The aim of this study was to evaluate the in vitro activity of the combination ceftazidimeavibactam at a fixed avibactam concentration of 4 mg/liter (19) compared with other ␤-lactam antibiotics, such as ceftaroline, which is the active compound of ceftaroline fosamil, ceftazidime, piperacillin, piperacillin-tazobactam, aztreonam, imipenem, and meropenem, against fluoroquinolone-resistant Enterobacteriaceae and P. aeruginosa clinical isolates and against laboratory-generated fluoroquinolone-resistant mutants of the aforementioned microorganisms with a well-defined mechanism of resistance to quinolones.
A
vibactam is a new broad-spectrum non-␤-lactam ␤-lactamase inhibitor with activity against clinically relevant enzymes belonging to Ambler classes A, C, and some D (e.g., extended-spectrum ␤-lactamase [ESBL] , Klebsiella pneumoniae carbapenemase [KPC] , AmpC, and OXA-48) but not to class B ␤-lactamases (1-3).
Strains that harbor such ␤-lactamases are increasing in prevalence worldwide, are among the most important and frequently isolated nosocomial pathogens, and are often additionally resistant to many classes of antibiotics, such as the fluoroquinolones (4) . It is known, mainly in Pseudomonas aeruginosa but also in Enterobacteriaceae, that the overexpression of some efflux pumps that confer resistance to fluoroquinolones, often associated with other mechanisms, such as mutations in genes encoding DNA gyrase and topoisomerase IV or acquisition of some plasmid-mediated quinolone-resistance genes, may increase the MIC of ␤-lactam antibiotics, such as ceftazidime (5) . The aim of this study was to evaluate the in vitro activity of the combination ceftazidimeavibactam at a fixed avibactam concentration of 4 mg/liter (19) compared with other ␤-lactam antibiotics, such as ceftaroline, which is the active compound of ceftaroline fosamil, ceftazidime, piperacillin, piperacillin-tazobactam, aztreonam, imipenem, and meropenem, against fluoroquinolone-resistant Enterobacteriaceae and P. aeruginosa clinical isolates and against laboratory-generated fluoroquinolone-resistant mutants of the aforementioned microorganisms with a well-defined mechanism of resistance to quinolones.
MATERIALS AND METHODS
Bacterial strains. A series of 200 Enterobacteriaceae and 25 P. aeruginosa strains resistant to fluoroquinolones (mainly from urinary tract infections and bacteremia occurring in different patients) were collected as consecutive clinical isolates in our institution (Hospital Clinic, Barcelona, Spain). Enterobacteriaceae and P. aeruginosa isolates were considered resistant to fluoroquinolones according to EUCAST breakpoints for ciprofloxacin. Some Enterobacteriaceae isolates showing a MIC above the epidemiological cutoff but considered to be susceptible according EUCAST rules (0.064 to Յ0.5 mg/liter) and with any mechanism of resistance to fluoroquinolones were also studied. Species identification was performed using matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (Bruker Daltonics, Bremen, Germany). An ESBL screen-positive phenotype was defined according to CLSI guidelines (6) . Enterobacteriaceae and P. aeruginosa were considered resistant to ceftazidime using the CLSI breakpoints for ceftazidime (Ͼ16 mg/liter and Ͼ32 mg/liter, respectively). The collection included Escherichia coli (n ϭ 60; 50% ESBL), K. pneumoniae (n ϭ 40; 50% ESBL), Enterobacter cloacae (n ϭ 25; 20% ceftazidime resistant), Citrobacter freundii (n ϭ 25; 68% ceftazidime resistant), Serratia marcescens (n ϭ 25; 20% ceftazidime re- (6) . The EUCAST breakpoints for ciprofloxacin were used to assess fluoroquinolone resistance, and some isolates showing a ciprofloxacin MIC of Յ0.5 mg/liter but possessing a mechanism of resistance to fluoroquinolones were also included in the study. E. coli ATCC 25922 and P. aeruginosa ATCC 27853 strains were used as reference strains for quality control of in vitro susceptibility testing.
Detection of ␤-lactamases. Isolates with ESBL phenotypes were characterized by PCR and sequencing, as described before (7). Ceftazidimeresistant species showing an AmpC-overproduction phenotype or a plasmid-mediated AmpC phenotype were confirmed using a ceftazidime or cefotaxime-boronic acid synergy test with 30 g ceftazidime or cefotaxime discs (Becton Dickinson, Sparks, MD, USA) together with 400 g phenylboronic acid (Sigma-Aldrich Co., St. Louis, MO, USA) (8) .
Detection of the mechanisms of resistance to quinolones. Detection of mutations in the DNA gyrase and topoisomerase IV genes were studied by amplifying and sequencing the quinolone resistance-determining regions (QRDRs) of the gyrA, gyrB, parC, and parE genes by PCR, using primers described before (9-13). Investigation of plasmid-mediated quinolone resistance (PMQR) genes was performed via screening by PCR of qnrA, qnrB, qnrS, aac(6=)Ib-cr, and qepA genes. The aac(6=)Ib-cr gene was sequenced in all isolates. Overexpression of efflux pumps was investigated by performing ciprofloxacin, norfloxacin, and nalidixic acid MIC measurements using Etest strips (AB bioMérieux, Solna, Sweden) in Mueller-Hinton agar (Becton Dickinson, Sparks, MD, USA) in the absence and presence of 20 mg/liter phenylalanine-arginine-␤-naphthylamide (PA␤N; Becton Dickinson, Sparks, MD, USA), an efflux pump inhibitor.
Selection of mutants. Mutants were selected by following either a single-or multiple-step selection method. To perform a single-step selection method, an inoculum (10 9 CFU/ml) from an overnight broth culture was spread on Mueller-Hinton agar (Becton Dickinson, Sparks, MD, USA) supplemented with ciprofloxacin at 2 to 4ϫ the MICs previously found. After overnight incubation, mutants with MICs that were Ն2-fold the MIC of ciprofloxacin were retained.
In the multiple-step selection method, several passages were performed. An inoculum (10 8 CFU) was added to 10-ml aliquots of nutrient broth containing ciprofloxacin at the MICs found previously and incubated for up to 48 h. This was repeated daily, each time doubling the ciprofloxacin concentration. Daily subculturing was performed until mutants with MICs that were Ն2-fold the MIC of ciprofloxacin were streaked to single colonies and retained.
RESULTS
Using the CLSI breakpoints for ceftazidime (Յ4 mg/liter for susceptibility), ceftazidime-avibactam was among the most active agents tested against the panel of fluoroquinolone-resistant Enterobacteriaceae (ciprofloxacin MIC of Ն0.5 mg/liter) studied (Table  1) , with 99.7% susceptibility. Similarly, 96% of fluoroquinoloneresistant P. aeruginosa strains were inhibited by Յ8 mg/liter of ceftazidime-avibactam (using the CLSI susceptibility breakpoint for ceftazidime alone as a reference).
All fluoroquinolone-resistant E. coli isolates were inhibited by (Table 2) .
When tested against fluoroquinolone-resistant ESBL-producing (mainly CTX-M-15, CTX-M-1, and SHV-12) ( Table 2 ) and non-ESBL-producing K. pneumoniae isolates, ceftazidimeavibactam inhibited all isolates below the ceftazidime breakpoint (MIC 90 of 0.25 mg/liter), and the highest MIC was 1 mg/liter.
Of the 25 fluoroquinolone-resistant C. freundii isolates, 17 were ceftazidime resistant; 4 of these were carrying ESBL enzymes, and 13 showed AmpC overproduction. All C. freundii isolates had ceftazidime-avibactam MIC values below the susceptibility breakpoint of ceftazidime alone. All ceftazidime-susceptible strains were inhibited by Յ0.125 mg/ml ceftazidime-avibactam, and ceftazidime-avibactam was active against all ceftazidime-resistant strains (MIC 90 of 1 mg/liter).
Ceftazidime-avibactam was active against 25 fluoroquinoloneresistant E. cloacae strains (MIC 90 of 0.5 mg/liter), including 5 ceftazidime-resistant strains that showed AmpC overproduction; the highest MIC detected was 1 mg/liter. In addition, ceftazidimeavibactam inhibited all strains of fluoroquinolone-resistant P. mirabilis (MIC 90 of 0.5 mg/liter), including seven ceftazidime-resistant strains showing a plasmid-AmpC production phenotype. The highest MIC observed in fluoroquinolone-resistant P. mirabilis isolates was, again, 1 mg/liter.
Twenty-five fluoroquinolone-resistant S. marcescens isolates, including 5 with ceftazidime resistance, were tested. All strains but one were inhibited by Յ4 mg/liter ceftazidime-avibactam (MIC 90 of 1 mg/liter). One ceftazidime-resistant strain that showed an AmpC overproduction phenotype was not inhibited by ceftazidime-avibactam (MIC of 128 mg/liter).
Finally, MIC 90 values of ceftazidime-avibactam for 25 fluoroquinolone-resistant P. aeruginosa clinical isolates are also shown in Table 1 . Ninety-six percent of isolates were inhibited by Յ8 mg/liter ceftazidime-avibactam (MIC 90 of 8 mg/liter). For the six isolates that were ceftazidime resistant, avibactam reversed ceftazidime resistance in 5 instances, while the remaining isolate was inhibited by 16 mg/liter ceftazidime-avibactam. Remarkably, ceftazidime-avibactam showed very good activity against meropenem-nonsusceptible P. aeruginosa (16 isolates), with 90% inhibited by Յ8 mg/liter ceftazidime-avibactam. This may be due to a loss of porins, mainly OprD, that affect carbapenems but not ceftazidime; however, further investigation is necessary to confirm this hypothesis.
The activity of quinolones against fluoroquinolone-resistant Enterobacteriaceae is presented in Table 3 . Mechanisms of fluoroquinolone resistance detected and the associated ceftazidimeavibactam MIC ranges are shown in Table 4 . Most of the fluoroquinolone-resistant strains studied (n ϭ 200; 88.9%) showed mutations in gyrA and/or parC, gyrB, or parE QRDR regions. Twenty-five percent of the isolates did not have mutations in QRDR regions. PMQR genes were detected in 20 strains (K. pneumoniae, n ϭ 9; E. cloacae, n ϭ 8; C. freundii, n ϭ 3); PMQR genes and overexpression of an efflux pump were observed in 3 strains (S. marcescens, n ϭ 2; K. pneumoniae, n ϭ 1), and 2 K. pneumoniae strains showed only an efflux pump overexpression. The ceftazidime-avibactam MIC ranges were not noticeably affected by the detected fluoroquinolone-resistance mechanisms, except in one S. marcescens strain that showed mutations in the QRDR regions.
The ceftazidime mechanisms of resistance in Enterobacteriaceae and associated ceftazidime MIC ranges are shown in Table 2 . No changes in the ranges of the ceftazidime-avibactam MIC and ceftazidime resistance mechanisms were detected, except in one S. marcescens strain that showed AmpC overproduction.
When mutant strains resistant to fluoroquinolones were generated by selection in vitro, all Enterobacteriaceae and P. aeruginosa strains tested were inhibited by Յ4 and Յ8 mg/liter of ceftazidime-avibactam, respectively (Table 5 ). For the large majority of the strains, no significant increases in the ceftazidime-avibactam MICs were observed. Among 13 fluoroquinolone-resistant mutant strains, one 4-fold ceftazidime-avibactam MIC increase (0.25 mg/liter to 1 mg/liter) was observed in the strain S. marcescens 243 and its mutant strain, S. marcescens 272, which was inhibited by 8 mg/liter of ceftazidime due to AmpC overproduction. In this strain, the fluoroquinolone resistance mechanism detected was efflux pump overexpression.
DISCUSSION
The purpose of this study was to examine the activity of ceftazidime-avibactam against fluoroquinolone-resistant clinical iso- Table 1 , against fluoroquinolone-resistant ESBL-carrying strains, inhibiting all isolates at Ͻ1 mg/liter. In addition to studying E. coli and K. pneumoniae that are ESBL producers, we also studied a group of ceftazidime-resistant (MIC of Ͼ16 mg/liter) C. freundii, E. cloacae, P. mirabilis, and S. marcescens strains that have stably derepressed chromosomal AmpC. The MIC 90 of ceftazidime-avibactam for these clinical isolates was 1 mg/liter. For isolates of Enterobacteriaceae that were nonsusceptible to ceftazidime, the addition of 4 mg/liter avibactam in ceftazidime-avibactam greatly increased the activity of ceftazidime against all species, as was found previously in a study performed in the United States on clinical isolates from bloodstream, pneumonia, intra-abdominal, and urinary tract infections (15) . One Serratia marcescens strain inhibited by Ͼ128 mg/liter of ceftazidime was not inhibited by the combination of ceftazidimeavibactam (MIC of 128 mg/liter), despite susceptibility to imipenem and meropenem. The mechanism of resistance may be associated with porin loss, thus restricting ceftazidime and/or avibactam entry, but further studies would be needed to elucidate this hypothesis.
As seen in other studies (2, (15) (16) (17) , avibactam increased the activity of ceftazidime against ceftazidime-resistant P. aeruginosa strains. Moreover, ceftazidime-avibactam was highly active against meropenem-nonsusceptible strains (MIC 90 of 8 mg/liter), as also shown by Sader et al. (18) . Although resistance to ceftazidime in this microorganism is usually considered multifactorial, most of the strains showed overexpression of the chromosomally encoded AmpC ␤-lactamase and, occasionally, acquisition of ESBLs such as PER-1, which may explain this inhibition.
Fluoroquinolone-resistant strains were also selected in vitro from parent strains that were both susceptible and resistant to ceftazidime alone (Table 5 ). These newly fluoroquinolone-resistant Enterobacteriaceae strains exhibited MICs against ceftazidime ranging from Ͻ0.125 mg/liter to Ͼ128 mg/liter. However, ceftazidime-avibactam retained potency with MICs in a range of Ͻ0.125 mg/liter to 1 mg/liter. When fluoroquinolone-resistant mutant strains of P. aeruginosa were obtained in a similar manner, a significant increase in the ceftazidime-avibactam MIC was not observed. When characterized, most of the mutant strains showed efflux pump overexpression as their mechanism of fluoroquinolone resistance. This and other target-specific resistance mechanisms had no effect on the activity of ceftazidime-avibactam.
In conclusion, ceftazidime-avibactam demonstrated potent in vitro activity against a collection of 200 Enterobacteriaceae and 25 P. aeruginosa strains resistant to fluoroquinolones, including ESBL-carrying and AmpC-overproducing strains, collected as consecutive clinical isolates in our institution. The specific resistance mechanisms detected were mutations in gyrA, gyrB, parC, and parE genes, in PMQR genes qnrA, qnrB, qnrS, aac(6=)Ib-cr, and qepA, and in efflux pumps. This work shows that resistance to fluoroquinolones has minimal effects on the potent activity of ceftazidime-avibactam against both ESBL and non-EBSL strains. The combination ceftazidime-avibactam thus may provide an ex- 
